Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943276 | 0.87 | L3MBTL1 (0.50) | L3MBTL1GRM2KLKB1SMN1; SMN2MMP13 | |
| SCHEMBL17546560 | 0.87 | KLKB1 (0.57) | L3MBTL1GRM2KLKB1SMN1; SMN2MLLT1 | |
| SCHEMBL17546565 | 0.81 | KLKB1 (0.63) | L3MBTL1GRM2KLKB1SMN1; SMN2CYP1A2 | |
| SCHEMBL1050914 | 0.78 | MMP13 (0.50) | L3MBTL1GRM2KLKB1SMN1; SMN2MMP13 | |
| SCHEMBL3266560 | 0.77 | GRM2 (0.42) | L3MBTL1GRM2 | |
| SCHEMBL24253400 | 0.75 | KCNA3 (0.41) | L3MBTL1GRM2CYP2C9CYP2C19 | |
| SCHEMBL17546602 | 0.75 | KLKB1 (0.63) | L3MBTL1GRM2KLKB1MMP13 | |
| SCHEMBL12911102 | 0.73 | P2RX7 (0.42) | GRM2CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL22231667 | 0.73 | KCNA3 (0.39) | GRM2 | |
| SCHEMBL12231396 | 0.73 | GRM2 (0.63) | L3MBTL1GRM2KLKB1SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318375-B1 | IMIDAZOLE CARBOXAMIDES | LILLY CO ELI (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2318375-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2010009062-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | CYP3A4, CYP2C9, AADAC | L3MBTL1 4877/4885GRM2 2836/4885EPHX2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.